RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating

MannKind Corporation (NASDAQ:MNKD) is one of the High Growth Penny Stocks That Are Profitable in 2025. On July 23, RBC Capital’s analyst Douglas Miehm lowered the firm’s price target on MannKind Corporation (NASDAQ:MNKD) from $10 to $8, while maintaining a Buy rating on the stock.

The analyst believes the current stock price reflects an overly pessimistic view of MannKind Corporation (NASDAQ:MNKD)’s products, particularly the Tyvaso DPI royalties, and assigns no value to the company’s product pipeline. During the fiscal first quarter of 2025, the company noted that its Afrezza, an inhaled insulin, saw 20% new prescription growth and 14% total prescription growth year-over-year. Moreover, the insulin’s pediatric Phase 3 trial is progressing, and the company also met with the FDA’s plan file for its approval in mid-2025.

MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapeutic products for diabetes and rare lung diseases.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.